Female Libido Enhancement for Improved Sexual Satisfaction
Flibanserin
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 12 | $4.00 | $48.00 (0%) | 🛒 Add to cart |
| 24 | $3.79 | $96.00 $91.00 (5%) | 🛒 Add to cart |
| 36 | $3.50 | $144.00 $126.00 (12%) | 🛒 Add to cart |
| 60 | $3.40 | $240.00 $204.00 (15%) | 🛒 Add to cart |
| 88 | $3.00
Best per pill | $352.00 $264.00 (25%) | 🛒 Add to cart |
Synonyms | |||
Female sexual dysfunction represents a complex medical condition affecting millions of women worldwide, characterized by persistent or recurrent reduction in sexual desire, arousal difficulties, or inability to achieve orgasm. Unlike the well-defined physiological mechanisms of male erectile dysfunction, female sexual health involves intricate neurovascular, hormonal, and psychological components. This comprehensive guide examines pharmaceutical interventions specifically developed to address these multifaceted concerns through evidence-based approaches.
Features
- Contains flibanserin 100mg as the active pharmaceutical ingredient
- Formulated as immediate-release oral tablets
- Requires prescription and medical supervision
- Specifically indicated for premenopausal women with hypoactive sexual desire disorder (HSDD)
- Works through central nervous system modulation rather than direct vascular effects
- Clinical trials demonstrate statistically significant improvement in satisfying sexual events
- Manufactured under strict FDA-approved quality standards
- Available in blister packs with child-resistant packaging
Benefits
- Increases spontaneous sexual desire and reduces distress associated with low libido
- Enhances overall sexual satisfaction and intimacy in relationships
- Provides a pharmaceutical option for women experiencing acquired, generalized HSDD
- Addresses the neurochemical imbalance associated with inhibited sexual desire
- Offers a non-hormonal approach to female sexual dysfunction
- Improves sexual function as measured by validated patient-reported outcomes
Common use
This medication is specifically indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). HSDD is characterized by persistently or recurrently deficient sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. The condition must not be better accounted for by another medical or psychiatric condition, relationship problems, or the effects of medication or drug use. Clinical studies have demonstrated efficacy in women who experience distress due to low sexual desire that cannot be attributed to existing medical or psychiatric conditions, relationship issues, or other medication side effects.
Dosage and direction
The recommended dosage is 100mg taken orally once daily at bedtime. Administration at bedtime helps mitigate potential side effects such as dizziness, somnolence, and fatigue. Tablets should be swallowed whole with water and not crushed or chewed. Treatment should be initiated under physician supervision after thorough evaluation. Consistent daily administration is necessary for therapeutic effect, which typically becomes noticeable after 4-8 weeks of continuous use. Dose adjustment is not recommended for elderly patients or those with renal impairment, but caution is advised in hepatic impairment. The medication should not be taken with alcohol or other central nervous system depressants.
Precautions
Patients should be cautioned about the potential for hypotension, syncope, and central nervous system depression. Alcohol consumption is contraindicated during treatment due to increased risk of severe hypotension and syncope. Use with caution in patients with hepatic impairment, as metabolism occurs primarily in the liver. Patients should avoid activities requiring complete mental alertness, such as driving or operating machinery, until they know how the medication affects them. Healthcare providers should assess patient’s concomitant medications for potential interactions. Regular follow-up appointments are recommended to monitor efficacy and safety parameters. Women of childbearing potential should use effective contraception during treatment.
Contraindications
This medication is contraindicated in patients with known hypersensitivity to flibanserin or any component of the formulation. Concomitant use with strong or moderate CYP3A4 inhibitors is prohibited due to increased flibanserin exposure. Patients with hepatic impairment should not use this medication. Concomitant alcohol use is absolutely contraindicated. The medication is not indicated for postmenopausal women or men. Use is contraindicated in patients with a history of hypotension or those taking antihypertensive medications. Patients with a history of depression or suicidal ideation require careful evaluation before initiation.
Possible side effects
Common adverse reactions include dizziness (11.4%), somnolence (11.2%), nausea (10.4%), fatigue (9.2%), and insomnia (4.9%). Less frequently reported effects include dry mouth, anxiety, constipation, and abdominal pain. Serious side effects may include syncope (0.4%), hypotension (0.2%), and central nervous system depression. Patients should be monitored for signs of hypotension, especially during initial treatment or dose adjustments. Some patients may experience changes in mood or worsening of pre-existing depression. The incidence of side effects generally decreases with continued therapy over time.
Drug interaction
Flibanserin is primarily metabolized by CYP3A4 and secondarily by CYP2C19. Concomitant use with strong CYP3A4 inhibitors increases flibanserin exposure approximately 7.5-fold and is contraindicated. Moderate CYP3A4 inhibitors increase exposure approximately 3.5-fold and should be avoided. Concurrent use with alcohol significantly increases the risk of severe hypotension and syncope. Use with other central nervous system depressants may potentiate sedation and dizziness. Flibanserin may increase the hypotensive effects of antihypertensive medications. Healthcare providers should conduct thorough medication reconciliation before prescribing and during treatment.
Missed dose
If a dose is missed at the usual bedtime time, patients should skip the missed dose and take the next dose at the regular time the following evening. Doubling the dose to make up for a missed dose is not recommended due to increased risk of adverse effects. Patients should maintain the regular dosing schedule and contact their healthcare provider if multiple doses are missed or if they have questions about dosage administration. Consistency in daily dosing is important for maintaining therapeutic effect.
Overdose
In case of suspected overdose, immediate medical attention should be sought. Symptoms may include severe dizziness, profound sedation, syncope, and hypotension. There is no specific antidote for flibanserin overdose. Treatment should consist of supportive measures including monitoring of vital signs, particularly blood pressure and heart rate. Gastric lavage may be considered if presented soon after ingestion. Activated charcoal may be administered if the patient presents within one hour of ingestion. Hemodialysis is not expected to be effective due to high protein binding. Patients should be monitored for at least 24 hours due to the medication’s half-life of approximately 11 hours.
Storage
Store at room temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container with the lid tightly closed to protect from moisture and light. Keep out of reach of children and pets. Do not use if the blister pack is damaged or tablets appear discolored or deteriorated. Properly dispose of unused or expired medication through medication take-back programs or according to FDA guidelines. Do not flush medications down the toilet or pour down the drain unless specifically instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual results may vary. This medication requires a prescription and should only be used under the supervision of a qualified healthcare provider. Patients should discuss their complete medical history, including all medications and supplements, with their physician before starting treatment. The FDA has approved this medication with a Risk Evaluation and Mitigation Strategy (REMS) program to ensure safe use. Only certified pharmacies and healthcare providers may prescribe and dispense this medication.
Reviews
Clinical trial data demonstrates that 53% of women treated with flibanserin reported meaningful improvement in sexual desire compared to 40% with placebo. Patients reported an average increase of 2.5 satisfying sexual events per month from baseline. Quality of life measures showed significant improvement in distress scores related to sexual desire. Real-world evidence suggests variable individual response, with some patients reporting substantial benefit while others experience limited improvement. Long-term studies indicate maintained efficacy with continued use up to 36 months. Patient satisfaction surveys show improved relationship satisfaction and reduced personal distress associated with low sexual desire.